Market research
TCDA Tricida Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 6M
- P/E ratio
- Not available
- Analyst target
- 20
- Dividend yield
- 0.0%
- Beta
- 0.21
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology & Medical Research
- ISIN
- US89610F1012
- Market cap
- 6M
- P/E ratio
- Not available
- Analyst target
- 20
- Dividend yield
- 0.0%
- Beta
- 0.21
About
About Tricida Inc
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company was incorporated in 2013 and is headquartered in South San Francisco, California. On January 11, 2023, Tricida, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the TCDA discussion.
5 years, 4 months ago
Tricida, Inc is currently in a long term downtrend where the price is trading 34.1% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Tricida, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has increased by 99.5% to $-265K since the same quarter in the previous year.
Finally, its free cash flow fell by 245.0% to $-104M since the same quarter in the previous year.
Based on the above factors, Tricida, Inc gets an overall score of 2/5.